{"anticipatedPostingDate":"2026-10","denomUnitsSelected":"Participants","description":"PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first. Analysis was performed using Kaplan-Meier method. Participants with no PD event or death or who started a new anticancer therapy prior to an event or with an event after a gap of 2 or more missing disease assessments were censored on the date of last adequate disease assessment. Participants who did not have an adequate post-baseline disease assessment were censored on the date of first dose of study intervention unless death occurred on or before the time of the second planned disease assessment (\\<=8 weeks after the date of first dose) in which case the death was considered an event.","reportingStatus":"NOT_POSTED","timeFrame":"Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)","title":"Progression Free Survival (PFS) Per IMWG Response Criteria as Determined by Investigator: Parts 1 and 2","type":"SECONDARY"}